

“New Horizons in Keratoderma Research”

Room C123 & C124, Oregon Convention Center, Portland, Oregon



Provisional Program

Tuesday 25th April 2017



12.00 Lunch and welcome reception

Session 1 Horizons in PC Research

1.30 Irwin McLean (University of Dundee, Dundee) – Introduction
Broadening our horizons to tackle the problem of keratoderma

2.00 Edel O’Toole (Queen Mary University of London, London) – Keynote Speaker 1
The clinical horizon – similarities and differences between PC and other PPKs

2.45 Eli Sprecher (Tel-Aviv Sourasky Medical Center, Tel-Aviv) – Keynote Speaker 2
The molecular horizon – the genes and proteins involved in PC and PPKs

3.30 Break

Session 2 Translational horizons

4.00 Pierre Coulombe (Johns Hopkins Bloomberg School of Public Health, Baltimore)
Mouse models of PC and PPK

4.30 Dennis Roop (University of Colorado, Denver)
Cellular reprogramming and gene editing therapy in genodermatology

5.00 Wes Kaupinen (Palvella Therapeutics, Philadelphia)
Topical Rapamycin: Update on PC Project & Palvella Therapeutics collaboration to rapidly advance towards the next clinical study

5.30 Bishr Omary (University of Michigan, Ann Arbor)
Small molecule approaches to treating pathogenic keratin aggregation

6:45 Meet in Martin Luther King Jr Lobby of Oregon Convention Center for transport to dinner

7.00 **Conference Dinner**
Portland City Grill, 111 SW Fifth Avenue, 30th Floor

Wednesday 26th April 2017

8.00 Breakfast buffet

Session 3 Scanning the PC pain and itch horizons

9.00 Michael Polydefkis (Johns Hopkins Medicine, Baltimore)
Pain in PC – why is it a problem and what can we do about it?

9.30 Thomas Magin (University of Leipzig, Leipzig)
Keratins at the crossroads of itch and mechanotransduction

10.00 Break

10.15 **Special Guest Lecture – Howard Chang (Stanford University, Stanford)**

**How does palmoplantar epidermis know that it is palmoplantar?
Molecular mechanisms controlling development and maintenance of ridged skin**

11.00 Break

Session 4 Towards new horizons – brainstorming session

11.30 Group discussion

Themes: Pain in PC

Therapeutic tractability of PPKs – what are the low-hanging fruit?

Drug repurposing in PPKs – genes and screens

Oligonucleotide therapeutics for PPKs

2018 meeting – onwards and upwards

12.30 Box lunch available and discussion continues

1.00 Close of meeting

